Karolinska Development – Q3 2016 Interim Report - invitation to conference call and webcast
November 17, 2016 02:00 ET
|
Karolinska Development AB
Please dial in at one of the following numbers a few minutes before the start of the conference call:
From Sweden: +46 (0) 8 505 564 74
From the US: +1 855 753 22...
Karolinska Development company Modus Therapeutics’ ongoing clinical study with sevuparin in sickle cell disease expands to include adolescent patients
November 15, 2016 02:00 ET
|
Karolinska Development AB
Details from the Modus Therapeutics press release follow:
A planned independent Data Safety Monitoring Board (DSMB) review has been conducted in the multi-centre, randomized Phase II clinical...
Karolinska Development company Modus Therapeutics granted U.S. patents for sickle cell disease drug candidate sevuparin
November 07, 2016 02:00 ET
|
Karolinska Development AB
Details from the Modus Therapeutics press release follow:
The two patents granted by the United States Patent and Trademark Office (USPTO) will provide key intellectual property protection in the...
Karolinska Developments bolag Umecrine Cognition meddelar positiva Fas 1-data med GR3027 mot hepatisk encefalopati
November 03, 2016 03:00 ET
|
Karolinska Development AB
Detaljer från Umecrine Cognitions pressrelease:
“Vi är mycket uppmuntrade av den farmakodynamiska effektmålet hos GR3027 i våra Fas 1-försök, samt med dess fördelaktiga säkerhets-...
Karolinska Development company Umecrine Cognition announces positive Phase 1 data with GR3027 in hepatic encephalopathy
November 03, 2016 03:00 ET
|
Karolinska Development AB
Details from the Umecrine Cognition press release follow:
“We are very encouraged by the pharmacodynamic effect of GR3027 in our Phase 1 trials, along with its favorable safety and...
Karolinska Development portfolio company Promimic AB appoints new Chairman and Directors to its Board
October 27, 2016 03:32 ET
|
Karolinska Development AB
Tord Lendau brings to Promimic more than 32 years’ of international leadership and board experience from innovative, rapid growth companies. Most recently, he was General Manager at Sandvik MedTech,...
Karolinska Development company Dilaforette to change name to Modus Therapeutics and announces intention to conduct an Initial Public Offering
October 20, 2016 02:00 ET
|
Karolinska Development AB
Modus Therapeutics (www.modustx.com) is a clinical-stage drug development company developing new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in rare...
Karolinska Developments bolag Dilaforette byter namn till Modus Therapeutics och meddelar sin avsikt att genomföra en börsintroduktion
October 20, 2016 02:00 ET
|
Karolinska Development AB
Modus Therapeutics (www.modustx.com) är ett läkemedelsbolag i det kliniska skedet som utvecklar nya farmaceutiska terapier för att återställa begränsat blodflöde och syretransport i ovanliga...
Karolinska Development portfolio company Promimic and Danco announce completion of US production line for HAnano Surface medical implant coating
October 19, 2016 02:00 ET
|
Karolinska Development AB
Details from the Promimic press release follow:
Promimic and Danco entered a strategic partnership in March 2016 under which Danco became the preferred process partner for Promimic for...
Karolinska Development portfolio company Aprea Therapeutics enrolls first patients in Phase II trial of APR-246 in ovarian cancer
October 10, 2016 03:00 ET
|
Karolinska Development AB
Details from the Aprea announcement follow:
“The initiation of the Phase II clinical study marks an important milestone for Aprea,” said Christian S. Schade, President and Chief Executive...